Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADACEL booster immunogenicity vs local DT/Td vaccines in Chinese children, adolescents and adults
CTR20131162Phase 3Active
- Sponsor
- Sanofi
- Start
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of acellular pertussis vaccine in diphtheria, Tetanus and pertussis (4 arms), sponsored by Sanofi. Primary endpoints: Seroprotection rate for diphtheria at Day 28, Pertussis booster response rate at Day 28 and 1 more. Started Apr 2014; status: active.
02
Drugs
acellular pertussis vaccine
03
Conditions
diphtheriaTetanuspertussis
Beyond the preview
Go deeper on CTR20131162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131162.